RT Journal Article
SR Electronic
T1 The decline of COVID-19 severity and lethality over two years of pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.01.22277137
DO 10.1101/2022.07.01.22277137
A1 Marziano, Valentina
A1 Guzzetta, Giorgio
A1 Menegale, Francesco
A1 Sacco, Chiara
A1 Petrone, Daniele
A1 Urdiales, Alberto Mateo
A1 Del Manso, Martina
A1 Bella, Antonino
A1 Fabiani, Massimo
A1 Vescio, Maria Fenicia
A1 Riccardo, Flavia
A1 Poletti, Piero
A1 Manica, Mattia
A1 Zardini, Agnese
A1 d’Andrea, Valeria
A1 Trentini, Filippo
A1 Stefanelli, Paola
A1 Rezza, Giovanni
A1 Palamara, Anna Teresa
A1 Brusaferro, Silvio
A1 Ajelli, Marco
A1 Pezzotti, Patrizio
A1 Merler, Stefano
YR 2022
UL http://medrxiv.org/content/early/2022/07/02/2022.07.01.22277137.abstract
AB Undernotification of SARS-CoV-2 infections has been a major obstacle to the tracking of critical quantities such as infection attack rates and the probability of severe and lethal outcomes. We use a model of SARS-CoV-2 transmission and vaccination informed by epidemiological and genomic surveillance data to estimate the number of daily infections occurred in Italy in the first two years of pandemic. We estimate that the attack rate of ancestral lineages, Alpha, and Delta were in a similar range (10-17%, range of 95% CI: 7-23%), while that of Omicron until February 20, 2022, was remarkably higher (51%, 95%CI: 33-70%). The combined effect of vaccination, immunity from natural infection, change in variant features, and improved patient management massively reduced the probabilities of hospitalization, admission to intensive care, and death given infection, with 20 to 40-fold reductions during the period of dominance of Omicron compared to the initial acute phase.Competing Interest StatementM.A. has received research funding from Seqirus. The funding is not related to COVID-19. All other authors declare no competing interest.Funding StatementM.M., G.G., V.M., P.Po., F.T. and S.M. acknowledge funding from EU grant 874850 MOOD. The contents of this publication are the sole responsibility of the authors and don't necessarily reflect the views of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProcessed data and code will be made available in a public repository